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RESEARCH CORRESPONDENCE
Dietary nitrate increases exercise
tolerance in patients with non-ischemic,
dilated cardiomyopathy—a double-blind,
randomized, placebo-controlled,
crossover trial
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Venu Reddy Bijjam, MD,a
Ciara Blaine, BSc,a Philip E. James, PhD,d
and Liam Cormican, MDa,cQ1
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Sciences, University College Dublin, Belfield,
Dublin, Ireland; cRespiratory and Sleep
Diagnostics Department, Connolly Hospital,
Blanchardstown, Dublin, Ireland; and the
dWales Heart Research Institute, Cardiff
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Non-ischemicQ3 dilated cardiomyopathy (NIDCM) is de-
fined as left ventricular dysfunction in the absence of
causative coronary artery disease. It typically presents with
impaired effort tolerance, which is a major prognostic
factor.1
Nitric oxide (NO), a potent systemic vasodilator, is vital
for skeletal muscle contraction and contributes to matching
of blood flow and oxygen delivery necessary in active
skeletal muscle. NIDCM is associated with dysregulated
NO production, including decreased endothelial NOS
expression and NO release. Furthermore, NO therapy has
been shown to improve systemic circulation in NIDCM by
reducing right ventricular after-load.
There are 2 pathways facilitating NO synthesis in vivo.
The L-arginine–NO synthase pathway is well characterized
and, until recently, was considered the sole source of
endogenous NO. A second, NO synthase–independent
pathway has recently been discovered and was found to
be involved in simple reduction of dietary, inorganic nitrate
to nitrite and NO.2,3 Acute nitrate consumption has been
shown to increase blood nitrate/nitrite levels and exercise
performance in healthy, athletic, pulmonary vascular disease
(PVD),4 chronic obstructive pulmonary disease (COPD)5
and heart failure (HF) subjects.2 We hypothesized that
dietary nitrate supplementation could acutely improve
exercise capacity in NIDCM.
We recruited a group of ambulatory outpatients with
NIDCM (New York Heart Association Functional Class II
or III) who were on optimized therapy. Exclusion criteria
were use of organic nitrate therapy, and diabetes or
conditions affecting mobility. Our study received local
institutional review board approval.
Subjects were tested on 2 separate days, 7 days apart, in a
crossover fashion after consuming a light, self-selected, low-
nitrate breakfast and taking usual medications. On both
days, in an identical manner and at the same time of day, we
performed resting blood pressure (BP) measures, blood
draws and incremental shuttle-walk tests (ISWTs) before
and 3 hours after beverage consumption, as this time-line
has been shown to correspond to near peak blood nitrite
concentrations after nitrate consumption.4
Upon completion of Day 1 pre-supplementation assess-
ments, subjects were randomized in a double-blind, cross-
over trial design to consume 140 ml of either nitrate-rich
beet-root juice (NO3
–; 12.9 mmol nitrate) or nitrate-depleted
beet-root juice (PL;o0.5 mmol nitrate). The PL preparation
is identical in taste and appearance but has had the nitrate
removed by anion exchange, as described in a previous
study.6 At each visit, subjects underwent baseline assess-
ments followed by consumption of 140 ml of beverage
(NO3
– or PL) and rested quietly for 150 ! 10 minutes, when
all measures were repeated. Thus, subjects underwent
assessments on 4 occasions separated by a 7-day washout
period ( F1Figure 1), during which they were advised not to
change behaviors that would influence NO pharmacokinetics
or exercise capacity, specifically diet, exercise and medication.
Immediately before and after each of the 4 ISWTs,
subjects rated their dyspnea and leg fatigue on the Borg
scale and had oxygen saturation (SpO2, in percent) and heart
rate (HR) measured. BP was measured at the brachial artery
using a manual sphygmomanometer and stethoscope before
all 4 ISWTs.
Measurement of NO derivatives (nitrate/nitrite) in
biologic fluids reflects NO bioavailability and was analyzed
using the current “gold standard,” ozone-based chemilumi-
nescence analysis, on an NO analyzer (NOA280i; Sievers).
We based the sample size on our recent study with an
identical protocol among COPD subjects where a significant
treatment effect of nitrate on ISWT was observed on a
sample of 11 subjects.5 ΔNO3– and ΔPL data were compared
by using 2-tailed, paired t-tests for normally distributed data
and Wilcoxon’s test for non–normally distributed data.
Correlations were assessed using Pearson’s correlation
coefficient. The presence of a carryover effect was assessed
using 2-tailed, unpaired t-tests by comparing the observed
ISWT difference among those who received NO3
– followed
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by PL with those who received the opposite. All statistical
tests were conducted at the 2-sided 0.05 significance level
using SPSS for Windows (version 15.0).
Twelve subjects were recruited. There was 1 drop-out due
to loss to follow-up. Thus, 11 subjects completed the study
( T1Table 1). After NO3
– consumption, mean ISWT distance
increased by 65 ! 41 meters (431 to 496 meters, 15%),
whereas there was a decrease of 5 ! 35 meters (437 to 433
meters, 1%) after PL (p ¼ 0.0056). The mean and individual
ISWT distances after NO3
– and PL are shown in F2Figure 2a.
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33 not eligible (diabetes, 
n=10; orgnaic nitrates, n=7;
musculo-skeletal
abnormalitiy, n=17)
1patient excluded
(loss to follow up)
6 received betroot
juice second
5 received beetroot
juice
Day 1baseline assessments*
Day 8 baseline assessments*
Day1 post-beverage assessments*
12 Recruited
3 hour rest
Randomization
7day washout period
45 screened
5 received placebo
juice second
7received
placebo juice
Data analysis (n=11) 
3 hour rest 
Day 8 post-beverage assessments * 
Figure 1 Trial design. Assessments included resting blood pressure, blood draw, resting, pre-ISWT dyspnea and arterial oxygen
concentration, ISWT, post-ISWT dyspnea and arterial oxygen concentration. BRJ, beet-root juice; PL, placebo.
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Ten of the 11 subjects walked further after NO3
– (30 to 140
meters), whereas 1 had a decreased exercise capacity (–10
meters). However, after PL, only 4 subjects had increased
walking capacity (10 to 80 meters), but 7 walked shorter
distances (–10 to –60 meters). There was no significant
difference regarding SpO2, HR, dyspnea or leg fatigue score
(data not shown). Also, there was no difference in ISWT
distance, regardless of treatment sequence (p ¼ 0.24),
suggesting no carryover effect of theQ4 interventionQ5 .QT2 Table 2
The median and individual plasma nitrate and nitrite
concentrations pre- and post-beverage (NO3
– and PL) are
shown in Figure 2b and c. After NO3
–, median plasma nitrate
increased by 811.1 (range 649.5 to 1,142.2) mmol/liter, with
little change after PL (p ¼ 0.003). Similarly, median plasma
nitrite increased by 319.7 nmol/liter (250.6 to 978.2) after
NO3
–, whereas there was a small decrease after PL (–10
nmol/liter; p ¼ 0.003). There was no correlation between
absolute change in plasma nitrite and absolute change in
ISWT distance (r ¼ 0.0007, p ¼ 0.99; Figure 2d).
Mean systolic and diastolic BP and mean arterial pressure
(MAP) decreased after NO3
– (–2.7, –1.4 and –2 mm Hg,
respectively), but increased after PL (4.5, 2.7 and 3.3 mm Hg,
respectively). Changes did not reach statistical significance.
We found that acute consumption of NO3
– (12.9 mmol)
significantly increased plasma nitrate/nitrite and significantly
increased exercise capacity in NIDCM patients. Our findings
are supported by previous reports of increased exercise
capacity in selected clinical groups, including subjects with
PVD,4 COPD5 and HF2 after nitrate consumption.
We also observed an 18% increase in ISWT distance with
NO3
– (–1.5% to 39%), whereas PL led to a 2% decrease
(–17.6% to 11.6%). Similar to the NO response, there was
marked variation regarding ISWT response to NO3
–. It is
probable that differences in baseline fitness/NO bioavail-
ability, medications and NIDCM severity contribute to this
variation. Nevertheless, 10 of 11 subjects had increased
ISWT distance post-NO3
–.
Exercise capacity is regarded as a principal variable for
the evaluation of new therapeutic approaches in NIDCM.
Further, we have demonstrated that exercise capacity
represents an important prognostic factor related to future
mortality in NIDCM.1 Controversy remains regarding the
optimal test to assess exercise capacity in NIDCM. Herein
we have we utilized the ISWT as our primary end-point,
which represents a standardized procedure and has been
shown to strongly predict maximal aerobic capacity and
future outcome in HF.
Our observations are supported by recent trials in HF
patients. One trial used constant-intensity cycle cardiopul-
monary exercise testing to assess 17 HF patients with
preserved ejection fraction. Although there was no change
in exercise efficiency (primary end-point), there were
significant increases in exercise oxygen consumption, total
work performed, exercise duration and plasma NO
metabolites.2 A second trial used isokinetic dynamometry
to assess 9 HF patients with NIDCM and showed acutely
increased peak knee extensor power.3 It is of interest to
note that our trial and these trials utilized the same dose of
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Figure 2 Absolute changes in ISWT, plasma nitrate, plasma nitrate. Dotted lines represent each individual; bold line represents the group
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dietary nitrate delivered in the same fashion in a crossover
design. It is difficult to compare our results directly. We
noted an 18% increase in ISWT distance, whereas Zamani
et al described a comparable 14% increase with constant-
intensity cardiopulmonary exercise testing.2 Our use of
ISWT does not allow detailed physiologic data to be
gathered. However, we believe that the increased exercise
capacity we observed post-NO3
– is probably related to the
same mechanistic pathways uncovered in those earlier HF
trials, namely increased cardiac output, muscular oxygena-
tion and post-occlusive hyperemic flow, reduced aortic
augmentation index2 and increased skeletal muscle
strength.3
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Table 1 Baseline Characteristics of Overall Chronic Obstruc-
tive Disease Patients (n ¼ 11)
Characteristic Value
Age (years) 56 ! 11 (43–80)
Males [n (%)] 7 (64)
BMI (kg/m2) 32.5 ! 4.6 (25.7–40.8)
Obese [n (%)] 7 (64)
Smoking status [n (%)]
Current smoker 4 (36)
Ex-smoker 1 (9)
Life long non-smoker 6 (55)
NYHA functional class
II 9 (82)
III 2 (18)
MLwHFQ 13 !7 (9–29)
LVEF (Simpson’s rule, %) 35 ! 13 (15–50)
LVIDdQ6 (cm) 6.3 ! 0.7 (5.4–7.5)
Left atrial area (cm) 20.4 ! 4.4 (15.9–27.1)
Resting reart rate (BPM) 73 ! 18
Resting SBP (mm Hg) 118 ! 25
Resting DBP (mm Hg) 71 ! 12
BNP (ng/liter) (median ! IQR) 295 ! 228
Creatinine (reference range
45"110 μmol/liter)
93 ! 31
Sodium (reference range 135"145
mEq/liter)
141 ! 1
Pharmacotherapy
ACE-I 9 (82)
Aspirin 6 (55)
β-blockers 10 (91)
Diuretics 10 (91)
Sprionolactone 5 (45)
Digoxin 1 (9)
HTN 4 (36)
ECG
Normal QRS duration [n (%)] 7 (64)
Normal sinus rhythm [n (%)] 10 (91)
Atrial fibrillation [n (%)] 1 (9)
Data expressed as as mean ! standard deviation, unless noted
otherwise. ACE-I, angiotensin-converting enzyme inhibitor; BMI, body
mass index; BNP, brain-type natriuretic peptide; DBP, diastolic blood
pressure; HTN, hypertension; IQR, interquartile range; LVEF, left
ventricular ejection fraction; MLwHFQ, Minnesota Living with Heart
Failure Questionnaire; NYHA, New York Heart Association; SBP, systolic
blood pressure.
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As expected, NO3
– supplementation led to a significant
increase in plasma nitrite (48.5-fold) and particularly
nitrate (428-fold). Similar to our COPD trial,5 we observed
marked variation in response to exogenous nitrate despite an
identical dose and time interval (Figure 2b and c). We
cannot explain these variations, but it is likely that
differences in oral bacteria and stomach acidity, age and
medication are contributing factors. Further, we recently
reviewed data demonstrating a variation in metabolism of
exogenously administered nitrate when measured at a single
time-point (e.g., 3 hours), yet the extent of nitrite/nitrate
production (across 24 hours) was found to be largely
similar.7 The importance of our placebo-controlled design is
illustrated by our earlier demonstration of intra-individual
variability with repeat doses of NO3
–.7
Pharmacologic preparations of organic nitrate are used,
with varied success, to treat HF and NIDCM. It should be
noted that, despite their similar physiologic effects, organic
and inorganic nitrate (such as dietary nitrate) possess
different chemical structures and pharmacokinetics. The
potency of inorganic nitrate is much lower than that of
organic nitrate. However, organic nitrate may result in
tolerance and, when discontinued, rebound effects are often
evoked. In contrast, inorganic, dietary nitrates do not show
any signs of tolerance, and physiologic effects may be
potentiated with long-term ingestion.
Although our trial has some major limitations, including
the acute nature of the assessments and the small sample
size, we utilized a robust trial design among a cohort of
well-characterized NIDCM subjects. Dietary nitrate has
potential as a novel, therapeutic strategy to increase exercise
tolerance in NIDCM. Our preliminary results require
confirmation among larger samples in the long-term setting.
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